Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.M. Prieur.
Arthrites inflammatoires chroniques.
Rhumatologie pediatrique. Cap. 4, pp. 119-151
[2.]
J.T. Cassidy, R.E. Petty.
Juvenile rheumatoid arthritis.
Textbook of pediatric rheumatology. Cap. 12, pp. 218-321
[3.]
R. Schneider, M.H. Passo.
Juvenile rheumatoid arthritis.
Rheum Dis Clin N Am, 28 (2002), pp. 503-530
[4.]
R.E. Petty, T.R. Southwood, J. Baum, E. Bhettay, D. Glass, P. Manners, et al.
(The Task Force for the Classification Criteria). Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997.
J Rheumatol, 25 (1998), pp. 1991-1993
[5.]
J. De Inocencio Arocena.
Tratamiento de la artritis cronica juvenil. Evolucion y pronostico.
Manual practico de reumatologia pediatrica. Cap. VII. Mrl S.L, (1999), pp. 185-253
[6.]
N.T. Ilowite.
Current treatment of juvenile rheumatoid arthritis.
Pediatrics, 109 (2002), pp. 109-115
[7.]
J. Garcia-Consuegra Molina, R. Merino Munoz, J. de Inocencio Arocena.
Artritis idiopatica juvenil: tratamiento actual y perspectivas terapeuticas.
Rev Esp Reumatol, 30 (2003), pp. 338-347
[8.]
E.H.S. Choy, G.S. Panayi.
Cytokine pathways and joint inflammation in rheumatoid arthritis.
N Engl J Med, 344 (2001), pp. 907-916
[9.]
P. Woo.
Cytokine polymorphisms and inflammation. Pediatric Review.
Clin Exp Rheumatol, 18 (2000), pp. 767-771
[10.]
M.E. Weinblatt, D.E. Trentham, P.A. Fraser, D.E. Holdsworth, K.R. Falchuk, B.N. Weissman, et al.
Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.
Arthritis Rheum, 31 (1988), pp. 167-175
[11.]
E.H. Giannini, E.J. Brewer, N. Kuzmina, A. Shaikov, A. Maximov, I. Vorontsov, et al.
Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR doubleblind, placebo-controlled trial.
N Engl J Med, 326 (1992), pp. 1043-1049
[12.]
F. Halle, A.M. Prieur.
Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype.
Clin Exp Rheumatol, 9 (1991), pp. 297-302
[13.]
A. Ravelli, S. Viola, D. Migliavacca, N. Ruperto, A. Pistorio, A. Martini.
The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
J Pediatr, 135 (1999), pp. 316-320
[14.]
M. Seitz, M. Zwicker, P.M. Villiger.
Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American College of Rheumatology response groups to methotrexate.
J Rheumatol, 30 (2003), pp. 28-35
[15.]
M.A. Muzaffer, J.M. Dayer, B.M. Feldman, W. Pruzanski, P. Roux-Lombard, R. Schneider, et al.
Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of Juvenile Rheumatoid Arthritis.
J Rheumatol, 29 (2002), pp. 1071-1078
[16.]
N. Ruperto, K. Murray, V. Gerloni, N. Wulffraat, S. Oliveira, F. Flacini, et al.
A randomized trial of methotrexate in medium versus higher doses in children with juvenile idiopathic arthritis who failed on standard dose.
Ann Rheum Dis, 61 (2002), pp. 60-61
[17.]
E. Silverman, L. Spiegel, D. Hawkins, R. Petty, D. Goldsmith, L. Schomberg, et al.
An initial evaluation of the efficacy and safety of leflunamide (LEF) in children with polyarticular course juvenile rheumatoid arthritis ( JRA).
Arthritis Rheum, 44 (2001), pp. s272
[18.]
S. Padeh, J.H. Passwell.
Intraarticular corticosteroid injection in the management of children with chronic arthritis.
Arthritis Rheum, 41 (1998), pp. 1210-1214
[19.]
D.D. Sherry, L.D. Stein, A.M. Reed, L.E. Schanberg, D.W. Kredich.
Prevention of length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids.
Arthritis Rheum, 42 (1999), pp. 2330-2334
[20.]
B. Eberhard, B.S. Gottleib, J.E. Weis, D. Milojevic, N.T. Illowite.
Comparison of the intraarticular effectiveness of triamcinolone hexacetonide to triamcinolone acetonide in juvenile rheumatoid arthritis.
Arthritis Rheum, 46 (2002), pp. 1271
[21.]
H.I. Huppertz, A. Tschammler, A.E. Horwitz, K.O. Schwab.
Intraarticular corticosteroids for chronic arthritis in children: Efficacy and effects on cartilage and growth.
J Pediatr, 127 (1995), pp. 317-321
[22.]
L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, A.L. Weaver, et al.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
N Engl J Med, 337 (1997), pp. 141-147
[23.]
R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, et al.
Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group.
Lancet, 354 (1999), pp. 1932-1939
[24.]
E.W. St Clair, C.L. Wagner, A.A. Fasanmade, B. Wang, T.h. Schaible, A. Kavanaugh, et al.
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 1451-1459
[25.]
A. Den Broeder, L. Van de Putte, R. Rau, M. Schattenkirchner, P. Van Riel, O. Sander, et al.
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
J Rheumatol, 29 (2002), pp. 2288-2298
[26.]
R. Rau.
Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.
Ann Rheum Dis, 61 (2002), pp. 70-73
[27.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
The ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[28.]
R. Rau, O. Sander, P. Van Riel, L. Van de Putte, F. Hasler, M. Zaug, et al.
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (Lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
J Rheumatol, 30 (2003), pp. 680-690
[29.]
D.J. Lovell, E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, J.J. Nocton, et al.
Etanercept in children with polyarticular juvenile rheumatoid arthritis.
N Engl J Med, 342 (2000), pp. 763-769
[30.]
D.J. Lovell, E.H. Giannini, A. Reiff, O.Y. Jones, R. Schneider, J.C. Olson, et al.
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Arthritis Rheum, 48 (2003), pp. 218-226
[31.]
M.J. Elliot, P. Woo, P. Charles, A. Long-Fox, J.N. Woody, R.N. Maini.
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-α (cA2).
Br J Rheumatol, 36 (1997), pp. 589-593
[32.]
A.D. Billiau, F. Cornillie, C. Wouters.
Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children.
J Rheumatol, 29 (2002), pp. 1111-1114
[33.]
P. Lahdenne, P. Vahasalo, V. Honkanen.
Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Ann Rheum Dis, 62 (2003), pp. 245-247
[34.]
H. Schmeling, K. Mathony, V. John, G. Keyser, S.t. Burdach, G. Horneff.
A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.
Ann Rheum Dis, 60 (2001), pp. 410-412
[35.]
D.A. Kietz, P.H. Pepmueller, T.L. Moore.
Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period.
Ann Rheum Dis, 61 (2002), pp. 171-173
[36.]
R.A.G. Russo, M.M. Katsicas, M. Zelazko.
Etanercept in systemic juvenile idiopathic arthritis.
Clin Exp Rheumatol, 20 (2002), pp. 723-726
[37.]
J. Haapasaari, H. Kautiainen, S. Hannula, H. Pohjankoski, M. Hakala.
Good results from combining etanercept to prevailing DMARD therapy in refractory idiopathic arthritis.
Clin Exp Rheumatol, 20 (2002), pp. 867-870
[38.]
W. Kuis, N.M. Wulffraat, R.E. Petty.
Autologous stem cell transplantation: an alternative for refractory juvenile chronic arthritis.
Rheumatology, 38 (1999), pp. 737-738
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados